Viking Therapeutics, Inc.

NASDAQ:VKTX

64.61 (USD) • At close October 17, 2024
Bedrijfsnaam Viking Therapeutics, Inc.
Symbool VKTX
Munteenheid USD
Prijs 64.615
Beurswaarde 7,159,083,540
Dividendpercentage 0%
52-weken bereik 8.28 - 99.41
Industrie Biotechnology
Sector Healthcare
CEO Dr. Brian Lian Ph.D.
Website https://www.vikingtherapeutics.com

An error occurred while fetching data.

Over Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat

Vergelijkbare Aandelen

XBiotech Inc. logo

XBiotech Inc.

XBIT

7.54 USD

Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc.

ORMP

2.4 USD

Talkspace, Inc. logo

Talkspace, Inc.

TALK

2.74 USD

Profound Medical Corp. logo

Profound Medical Corp.

PROF

7.74 USD

Harrow Health, Inc. logo

Harrow Health, Inc.

HROW

56.41 USD

Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals Inc.

FUSN

21.55 USD

Beyond Air, Inc. logo

Beyond Air, Inc.

XAIR

0.345 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)